Pharmacogenetics of Warfarin Induction and Inhibition

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier:
NCT01447511
First received: January 29, 2010
Last updated: November 12, 2013
Last verified: November 2013

January 29, 2010
November 12, 2013
May 2009
June 2013   (final data collection date for primary outcome measure)
To measure warfarin clearance. [ Time Frame: Over three 12-16 day study periods. ] [ Designated as safety issue: No ]
The magnitude of the warfarin-fluconazole drug interaction in healthy volunteers genotyped for CYP2C9*1/ *1, *1/*3 or *3/*3 alleles by measuring warfarin enantiomer clearance.
Same as current
Complete list of historical versions of study NCT01447511 on ClinicalTrials.gov Archive Site
To measure prothrombin time. [ Time Frame: Over three 12-16 day study periods. ] [ Designated as safety issue: Yes ]
The magnitude of the warfarin-fluconazole drug interaction in healthy volunteers genotyped for CYP2C9*1/ *1, *1/*3 or *3/*3 alleles by measuring prothrombin time.
Same as current
Not Provided
Not Provided
 
Pharmacogenetics of Warfarin Induction and Inhibition
Pharmacogenetics of Warfarin Induction and Inhibition

This research study will help determine how a person's genetic makeup affects their response to drugs, the ability of the body to break down drugs, and their potential to experience an interaction between drugs. The investigators are investigating the drug interactions with the commonly used anticoagulant drug called warfarin. Warfarin is used for the treatment and prevention of life-threatening abnormal blood clots such as deep vein thrombosis, heart attacks, and strokes. The investigators chose warfarin for this study because it is a commonly used drug and must be monitored closely to avoid side effects. The investigators are interested in studying whether individuals with certain genetic profiles react differently to warfarin when it is combined with other drugs. This research is being done to see if certain genetic profiles require us to adjust warfarin doses differently than is needed for the general population. Genetic profiles of subjects are determined from their participation in the Pharmacogenetics Registry study (investigator Richard Brundage, University of Minnesota).

The study hypothesis is: Functionally defective CYP2C9 alleles attenuate the warfarin-fluconazole inhibitory interaction and exacerbate the warfarin-rifampin inductive interaction.

The research question is: How does CYP2C9 genotype modify warfarin drug interactions?

People differ in their genetic makeup. This includes differences in genes involved in drug metabolism, transport, and effect in the body. People with certain genetic profiles produce altered enzymes, transporters, and receptors that may respond in different ways to drugs. Altered enzymes cause some drugs to be broken down at a different rate than normal. As a result, drug concentrations build up in the blood, and increase the risk of side effects. Furthermore, when two drugs are taken together, the possibility exists for the drugs to interact, with one drug causing a change in the metabolism of the other or both of the drugs. It is not known whether people with an altered genetic makeup also have an altered experience with drug interactions. Altered drug transporters can affect the absorption and elimination of drugs as compared to normal causing differences in how long the drug stays in the body. Finally, altered drug receptors can respond differently to drugs and, thus, produce altered desired or undesired effects.

In this study, the investigators will be investigating the drug interactions with the commonly used anticoagulant drug warfarin in subjects with five different alleles of the CYP2C9 genotype. The CYP2C9 genotype is particularly important because this drug metabolizing enzyme governs the metabolic clearance of the more potent chemical entity (the S-enantiomer) of the drug. Warfarin is used for the treatment and prevention of life-threatening abnormal blood clots such as deep vein thrombosis, myocardial infarction, and strokes. The investigators chose warfarin for this study because it is a commonly used drug and must be monitored closely to avoid side effects. The investigators are interested in studying whether individuals with certain genetic alleles of the CYP2C9 genotype react differently to warfarin when it is combined with an antifungal (fluconazole) that inhibits CYP2C9-mediated metabolism and an antibiotic (rifampin) that induces CYP2C9-mediated metabolism. This research is being done to see if certain genetic profiles require us to adjust warfarin doses differently than is needed for the general population.

The study hypothesis is: Functionally defective CYP2C9 alleles attenuate the warfarin-fluconazole inhibitory interaction and exacerbate the warfarin-rifampin inductive interaction.

Observational
Observational Model: Case-Crossover
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Subjects are selected from a pharmacogenetics registry in which their drug metabolism genotype has been determined.

  • Warfarin
  • Drug Interactions
Drug: Warfarin

10 mg warfarin, taken once during each of three study periods. Study Period 1: Take 400mg of fluconazole by mouth every morning for about 3 weeks.

Study Period 2: Take 300mg of rifampin by mouth every morning for about 3 weeks.

Study Period 3: Take no medications during the study period.

Other Names:
  • Diflucan
  • Rifadin
  • Coumadin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
39
June 2013
June 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • subjects will be 18-60 years old.
  • Women of child bearing age must be willing to use measures to avoid conception during the study period.
  • Subjects must agree not to take any known substrates, inhibitors, inducers or activators of either CYP2C9 or CYP3A4 from 1 week prior to the start of each study through the last day of study.

Exclusion Criteria:

  • Current cigarette smoker
  • Abnormal renal, liver function tests, physical exam, or recent history of hepatic, renal, gastrointestinal or neoplastic disease.
  • Allergy to warfarin, fluconazole or rifampin and other chemically related drugs.
  • Recent ingestion (< 1 week) of any medication known to be metabolized by or alter CYP2C9 or CYP3A activity.
  • A positive pregnancy test at the time of the pharmacokinetic study.
  • Lab tests indicative of abnormal blood clotting capacity.
Both
18 Years to 60 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01447511
0807M38361, P01GM032165-26
No
University of Minnesota - Clinical and Translational Science Institute
University of Minnesota - Clinical and Translational Science Institute
National Institute of General Medical Sciences (NIGMS)
Principal Investigator: Richard Brundage, PhD University of Minnesota - Clinical and Translational Science Institute
University of Minnesota - Clinical and Translational Science Institute
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP